Tag:
smoking cessation
Latest Headlines
Latest Headlines
Chrono snares $32M in Series A for wearable smoking cessation device
Chrono Therapeutics secured $32 million in Series A funding the company will use to complete the development and clinical studies of its wearable SmartStop smoking cessation system.
Novartis dumps a long-faded $500M pact with Cytos
Close to six years after promising up to $500 million to gain rights to Zurich-based Cytos Biotechnology's ($CYTN) smoking cessation vaccine, Novartis has handed back the rights to the treatment and written off its investment.
CN Creative nails $3.1M for electronic inhaler smoking cessation device
CN Creative has secured $3.1 million in new financing to fund final development work for its electronic inhaler nicotine replacement therapy device to help patients quit smoking. Advent Life Sciences
Developer looks to nanoparticles for smoking cessation vaccine
Last week, Selecta Biosciences, a 2011 Fierce 15 company, announced that it has started a Phase I trial of a synthetic nanoparticle vaccine for smoking cessation. The shot, called SEL-068, is
Selecta starts trial of synthetic nano-vaccine for smoking
Boston-based Selecta Biosciences, a 2011 Fierce 15 winner, has kicked off a Phase I trial of nicotine vaccine SEL-068 for smoking cessation and relapse prevention. The company is touting its trial as
Ex-Amarin CEO's biotech strikes paydirt data on anti-smoking drug
A little-known biotech company founded by a group that includes Rick Stewart, the former CEO at Amarin, and focused on a single development project finds itself in the spotlight this morning. Extab,
Biomarker helps guide study on smoking cessation treatments
Building on new insights gained from the discovery of a biomarker that can be used to track individual differences for the rate at which nicotine breaks down in the body, a team of researchers at the
Cytos plummets on Phase II vax failure
Switzerland's Cytos Biotechnology (CYTN) stock was punished on the news that it's anti-smoking vaccine failed to hit its primary endpoint in a Phase II trial. This endpoint was defined as a
Somaxon secures cash for Silenor marketing
As Somaxon waits for the FDA okay on insomnia treatment Silenor, the company has lined up funding for marketing and commercialization of the drug. The company inked a $15 million secured loan
FDA overhauls trial design with new suicide standard
The FDA has quietly engineered the biggest change-up in the way many clinical trials are designed since the early '90s. Developers working in a range of fields including obesity, epilepsy, smoking
